Efavirenz (EFV) Intensification

Not Applicable

Completed

• Conditions: HIV
• Interventions: Drug: Efavirenz 600mg

• Registration Number: NCT07193875
• Lead Sponsor: Washington University School of Medicine

Brief Summary

The goal of this clinical trial is to see if Efavirenz (EFV) intensification to a baseline combination antiretroviral regimen (cART) can help reduce the size of the latent reservoir in people living with HIV (PLWH). The main questions this study aims to address are:

1. is the addition of EFV to a cART regimen safe and well tolerated?

2. Is there a reduction in the blood and tissue HIV reservoir after intensification?

Researchers will compare each participants reservoir size prior to and post EFV intensification.

Detailed Description

To evaluate the safety and tolerability of efavirenz (EFV) intensification on the HIV-1 reservoir. Participants with well controlled HIV, specifically with a HIV VL \<500 for at least 48 weeks will be eligible. Prior to enrollment, we will prescreen individuals to ensure they do not have a polymorphism in CY450 which results in rapid metabolism of the study drug efavirenz. Leukapheresis and lymph node (LN) fine needle aspirates will be collected at baseline. Participants eligible to participate will begin taking Efavirenz in addition to their baseline combination antiretroviral therapy. Blood samples (120ml) will be collected twice at day 30 and day 90 for cell associated HIV RNA and HIV DNA assessments. Follow-up LN aspirates and follow-up Leukapheresis will be collected at completion of study, between day 150-180, based on scheduling. At day 90 pharmacokinetic (PK) evaluation of EFV will take place to ensure therapeutic levels of Efavirenz. At the completion of the 180 day course of efavirenz, participants will stop efavirenz but continue their baseline HIV regimen. CD4, HIV VL and monitoring chemistries will be performed at visits on day 30, day 90 and day 150-180.

Study Timeline

• Status Verified: 2023-01
• Study Start: 2023-02-09
• Primary Completion: 2024-12-16
• Study Completion: 2024-12-16
• Study First Submitted: 2025-09-16
• Study First Submitted QC: 2025-09-22
• Last Update Submitted: 2025-09-22
• Study First Posted: 2025-09-26
• Last Update Posted: 2025-09-26

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 7

Inclusion Criteria

1. At least 18 years of age
2. Diagnosis of HIV
3. Documentation of at least two historical HIV-1 RNA measurements <500 copies/mL while on ART obtained by standard assay.
4. No known non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance mutations.
5. Currently on a stable regimen including an integrase strand transfer inhibitor (INSTI) and two nucleoside reverse transcriptase inhibitors (NRTI). Receiving the current regimen for at least 90 days prior to study entry with no intention to change for the duration of the study.

Exclusion Criteria

1. Untreated depression, defined as a PHQ-9 > 15 at time of enrollment
2. Known prior NNRTI resistance, or INSTI resistance.
3. Cytochrome 450 polymorphism resulting in rapid or delayed metabolism of Efavirenz
4. Not currently on a PI based regimen.
5. Does not have an immunocompromising medical condition. (ie malignancies particularly leukemia, lymphoma, use of immunosuppressive or antineoplastic drugs or X-ray treatment).
6. Chronic, acute, or recurrent infections that are current and serious, in the opinion of the site investigator.
7. Breastfeeding patients as well as those whom are pregnant or plan to become pregnant during period of the study.
8. Those with active Hepatitis C or Hepatitis B.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Efavirenz intensification	Efavirenz 600mg	There is only one arm in this study

Primary Outcome Measures

Name	Time	Method
Safety of Efavirenz intensification on a baseline cART regimen	3 months post completion of trial	Safety of Efavirenz intensification on a baseline cART regimen; The safety will be addressed both with laboratory tests (CBC, CMP, CD4, HIV VL) performed monthly, and PHQ9 surveys (for the rare reported adverse effect of worsening depression with Efavirenz) in addition to asking patients more subjective questions of how they are feeling and tolerating the medications and self reporting of (rash, pruritis, mood changes, nausea, vomiting or new abnormal symptoms).

Secondary Outcome Measures

Name	Time	Method
Size of the latent reservoir	within 2 years post study completion	Size of intact provirus pre and post Efavirenz intensification as measured by IPDA

Trial Locations

Locations (1)

Washington University in St Louis; 🇺🇸 St Louis, Missouri, United States